The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

被引:142
作者
Bremnes, RM [1 ]
Sundstrom, S
Aasebo, U
Kaasa, S
Hatlevoll, R
Aamdal, S
机构
[1] Univ Tromso Hosp, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Trondheim Hosp, Dept Oncol, N-7007 Trondheim, Norway
[3] Univ Tromso Hosp, Dept Pulm Med, N-9038 Tromso, Norway
[4] Norwegian Radium Hosp, Dept Oncol, N-310 Oslo, Norway
关键词
SCLC; limited disease; extensive disease; prognostic factors; survival;
D O I
10.1016/S0169-5002(02)00508-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have evaluated the prognostic value of 22 pretreatment attributes in 436 small cell lung cancer (SCLC) patients included in a prospective multicenter study with a minimum 5-year follow-up. Pretreatment clinical and laboratory parameters were registered. Possible prognostic factors were evaluated by univariate analysis (log rank test) and by the Cox multivariate regression model. In the univariate analysis of all patients, only age, nodal metastasis, and skin metastasis were not associated with survival. The multivariate Cox model identified gender, extent of disease, performance status (PS), weight loss, platelet count, LDH, and NSE as independent prognostic factors. In subset multivariate analyses according to extent of disease, we found haemoglobin level, PS, NSE, and total WBC as significant prognostic indicators for survival in limited-stage disease (LD-SCLC), while PS, weight loss, LDH, number of metastases, liver metastases, and brain metastases were identified as independent prognostic factors in extensive-stage disease (EDSCLC). There was a significant correlation between serum LDH and NSE levels. In conclusion, gender, extent of disease, PS, weight loss, haemoglobin, WBC count, platelet count, LDH, and NSE were all found to be independent prognostic factors for SCLC survival. However, the prognostic value of these factors depends highly on whether all or subsets of SCLC patients are studied. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:303 / 313
页数:11
相关论文
共 45 条
  • [1] DETERMINANTS OF IMPROVED OUTCOME IN SMALL-CELL LUNG-CANCER - AN ANALYSIS OF THE 2,580-PATIENT SOUTHWEST ONCOLOGY GROUP DATA-BASE
    ALBAIN, KS
    CROWLEY, JJ
    LEBLANC, M
    LIVINGSTON, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) : 1563 - 1574
  • [2] PROGNOSIS AT PRESENTATION OF SMALL-CELL CARCINOMA OF THE LUNG
    ALLAN, SG
    STEWART, ME
    LOVE, S
    CORNBLEET, MA
    SMYTH, JF
    LEONARD, RCF
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (06) : 703 - 705
  • [3] [Anonymous], 1981, HIST TYP LUNG TUM
  • [4] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
    Aupérin, A
    Arriagada, R
    Pignon, JP
    Le Péchoux, C
    Gregor, A
    Stephens, RJ
    Kristjansen, PEG
    Johnson, BE
    Ueoka, H
    Wagner, H
    Aisner, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) : 476 - 484
  • [5] Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer
    Bremnes, RM
    Sundstrom, S
    Vilsvik, J
    Aasebo, U
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) : 3532 - 3538
  • [6] Brugger W, 1998, SEMIN ONCOL, V25, P42
  • [7] PRETREATMENT PROGNOSTIC FACTORS AND SCORING SYSTEM IN 407 SMALL-CELL LUNG-CANCER PATIENTS
    CERNY, T
    BLAIR, V
    ANDERSON, H
    BRAMWELL, V
    THATCHER, N
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (02) : 146 - 149
  • [8] Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy
    Coates, A
    Porzsolt, F
    Osoba, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) : 1025 - 1030
  • [9] COHEN MH, 1979, CANCER TREAT REP, V63, P163
  • [10] COHEN MH, 1981, CANCER TREAT REP, V65, P187